Buprenorphine Transdermal System Patch, Extended Release
NDC Package 47781-408-04

11-digit billing NDC: 47781040804 · Billing unit: EA · 4 EA per package

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Buprenorphine Transdermal System (buprenorphine) patches is buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. This formulation utilizes a patch, extended release delivery system. Marketed by Alvogen Inc., this product is identified by NDC 47781-408 and is authorized under FDA application ANDA207490.

Identification & Billing

NDC Package Code
47781-408-04
Package Description
4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH (47781-408-11) / 168 h in 1 PATCH
Product Code
11-Digit Billing Format
47781040804
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
4 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Buprenorphine Transdermal System
Non-Proprietary Name
Buprenorphine
Substance Name
Buprenorphine
Dosage Form
Patch, Extended Release - A drug delivery system in the form of a patch that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form).
Administration Route
Transdermal - Administration through the dermal layer of the skin to the systemic circulation by diffusion.
Active Ingredient(s)
Usage Information
Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse and misuse with opioids, which can occur at any dosage or duration, and because of the greater risk of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1)], reserve buprenorphine transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic
DEA Schedule
Schedule III (CIII) Substances

Regulatory & Marketing

Labeler Name
Alvogen Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA207490
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-17-2022
End Marketing Date
01-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 47781-408-04 identifies a specific commercial package of 4 pouch in 1 carton / 1 patch in 1 pouch (47781-408-11) / 168 h in 1 patch of Buprenorphine Transdermal System, a human prescription drug labeled by Alvogen Inc.. This patch, extended release is formulated for transdermal use and contains buprenorphine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alvogen Inc. on May 17, 2022.

How is this Alvogen Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 47781040804. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
47781-408-04
11-Digit CMS (5-4-2)
47781-0408-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.